MA26629A1 - Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production - Google Patents

Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production

Info

Publication number
MA26629A1
MA26629A1 MA25577A MA25577A MA26629A1 MA 26629 A1 MA26629 A1 MA 26629A1 MA 25577 A MA25577 A MA 25577A MA 25577 A MA25577 A MA 25577A MA 26629 A1 MA26629 A1 MA 26629A1
Authority
MA
Morocco
Prior art keywords
sildeenfil
pharmaceutical preparation
orely
delenited
production
Prior art date
Application number
MA25577A
Other languages
English (en)
Inventor
Francis Dolan Thomas
Carol Gratlin Hausberge Angela
Bell-Huff Cristi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26629A1 publication Critical patent/MA26629A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)

Abstract

L'INVENTION CONCERNE UNE PRÉPARATION PHARMACEUTIQUE, à DÉLITEMENT ORAL, COMPRENANT DU SILDÉNAFIL SOUS FORME DE BASE LIBRE CONJOINTEMENT AVEC UN SUPPORT PHARMACEUTIQUEMENT ACCEPTABLE. ELLE CONCERNE ÉGALEMENT UN PROCÉDÉ POUR SA PRÉPARATION EN UTILISANT UN LIANT HYDRSOLUBLE POUVANT FONDRE, AU MOINS UN EXCIPIENT ET LE SILDÉNAFIL SOUS FORME DE BASE LIBRE. -APPLICATION : UTILISATION DE CETTE PRÉPARATION POUR LE TRAITEMENT DE DYSFONCTIONNEMENTS SUXUELS MASCULINS ET FÉMININS.
MA25577A 1998-05-15 1999-05-12 Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production MA26629A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
MA26629A1 true MA26629A1 (fr) 2004-12-20

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25577A MA26629A1 (fr) 1998-05-15 1999-05-12 Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production

Country Status (32)

Country Link
US (1) US20020002172A1 (fr)
EP (1) EP0960621A3 (fr)
JP (1) JPH11349483A (fr)
KR (1) KR19990088249A (fr)
CN (1) CN1251758A (fr)
AP (1) AP9901534A0 (fr)
AR (1) AR016481A1 (fr)
AU (1) AU753478B2 (fr)
BG (1) BG103396A (fr)
BR (1) BR9902086A (fr)
CA (1) CA2272042A1 (fr)
CO (1) CO5060503A1 (fr)
DZ (1) DZ2786A1 (fr)
EA (1) EA002830B1 (fr)
GT (1) GT199900061A (fr)
HN (1) HN1999000066A (fr)
HR (1) HRP990144A2 (fr)
HU (1) HUP9901606A2 (fr)
ID (1) ID23299A (fr)
IS (1) IS5046A (fr)
MA (1) MA26629A1 (fr)
NO (1) NO992339L (fr)
NZ (1) NZ335772A (fr)
OA (1) OA11040A (fr)
PA (1) PA8472901A1 (fr)
PE (1) PE20000546A1 (fr)
PL (1) PL333118A1 (fr)
SG (1) SG79255A1 (fr)
SK (1) SK61599A3 (fr)
TR (1) TR199901077A2 (fr)
YU (1) YU21999A (fr)
ZA (1) ZA993338B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346350C (fr) * 1998-10-05 2008-01-08 Eisai Co., Ltd. Comprimes se delitant rapidement dans la cavite buccale
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
EP1171134A4 (fr) * 1999-03-16 2005-01-05 Pentech Pharmaceuticals Inc Liberation controlee de sildenafil administre par voie sublinguale ou orale
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
ES2381862T3 (es) 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (fr) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (fr) * 2001-01-26 2002-07-31 Pfizer Products Inc. Formulation pharmaceutique présentant des propriétés de cohesion et de compressibilité améliorées
AU2002314044B2 (en) * 2001-05-09 2006-09-21 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
WO2006016530A1 (fr) * 2004-08-10 2006-02-16 Translational Research, Ltd. Composition transnasale dont l’action est immédiate et l’absorbabilité est élevée
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
CA2623657A1 (fr) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US20080261991A1 (en) * 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Reducing Side Effects of Tramadol
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
AU2010223105B2 (en) 2009-03-09 2016-05-12 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011030351A2 (fr) 2009-09-03 2011-03-17 Rubicon Research Private Limited Compositions pharmaceutiques au goût masqué
EP2338474A1 (fr) * 2009-12-23 2011-06-29 Ratiopharm GmbH Comprimé orodispersible contenant une base de sidénafil compactée
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
MX349803B (es) * 2011-02-11 2017-08-14 Ctc Bio Inc Preparación farmacéutica de película que contiene sildenafil en su forma de base libre y método para producir dicha preparación.
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法
CN121925251A (zh) * 2023-08-30 2026-04-24 陶氏环球技术有限责任公司 喷雾干燥的赋形剂共混物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
EP1171134A4 (fr) * 1999-03-16 2005-01-05 Pentech Pharmaceuticals Inc Liberation controlee de sildenafil administre par voie sublinguale ou orale

Also Published As

Publication number Publication date
HRP990144A2 (en) 2000-02-29
NO992339L (no) 1999-11-16
BG103396A (bg) 2000-01-31
GT199900061A (es) 2000-10-14
AP9901534A0 (en) 1999-06-30
AU2812699A (en) 1999-11-25
PA8472901A1 (es) 2000-09-29
AU753478B2 (en) 2002-10-17
DZ2786A1 (fr) 2003-12-01
EP0960621A2 (fr) 1999-12-01
IS5046A (is) 1999-11-16
CA2272042A1 (fr) 1999-11-15
TR199901077A3 (tr) 1999-12-21
NZ335772A (en) 2000-12-22
PE20000546A1 (es) 2000-07-07
BR9902086A (pt) 2000-05-02
YU21999A (sh) 2002-03-18
KR19990088249A (ko) 1999-12-27
TR199901077A2 (en) 1999-12-21
OA11040A (en) 2003-01-01
SK61599A3 (en) 2000-12-11
US20020002172A1 (en) 2002-01-03
EA199900373A2 (ru) 1999-12-29
CO5060503A1 (es) 2001-07-30
ZA993338B (en) 2000-11-14
SG79255A1 (en) 2001-03-20
EP0960621A3 (fr) 2000-01-05
JPH11349483A (ja) 1999-12-21
HN1999000066A (es) 1999-09-29
NO992339D0 (no) 1999-05-14
PL333118A1 (en) 1999-11-22
HU9901606D0 (en) 1999-07-28
EA199900373A3 (ru) 2000-08-28
CN1251758A (zh) 2000-05-03
AR016481A1 (es) 2001-07-04
ID23299A (id) 2000-04-05
HUP9901606A2 (en) 2002-09-28
EA002830B1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
DZ2237A1 (fr) 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA27037A1 (fr) Amides d'acide anthranilique avec une chaine laterale heteroarylsulfonyle, procede pour leur fabrication, leur utilisation comme medicament et comme agent de diagnostic ainsi que les preparations pharmaceutiques en contenant
YU21999A (sh) Farmaceutske smese i postupak za njihovo dobijanje
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
CA2318128A1 (fr) Compositions liquides orales
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
YU83502A (sh) Nova farmaceutska smeša
PT991653E (pt) Novos compostos
MA26747A1 (fr) Composes inhibiteurs de recepteurs de nmda, leurs utilisations dans le traitement de troubles neuronaux et leurs preparations
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MX9505065A (es) Composicion farmaceutica, aplicable oralmente.
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
YU52999A (sh) Kombinacija analgetika
MA26523A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant
EP1637139A3 (fr) Nouvelle utilisation de composés inhibiteurs de la protéase du VIH
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
EP0670166A3 (fr) Compositions pharmaceutiques administrables par voie buccale.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles